Must See: Robert Kennedy Reveals that COVID Vaccines Are a Pentagon Project!

February 27, 2023 in News by RBN Staff

 

RFK Jr. outing the Pentagon, and the actual document from the government detailing their involvement.

– Steve Elkins

 

Source: Need To Know (document from Congressional Research Service follows this story below)

Children’s Health Defense founder Robert F. Kennedy Jr. (RFK) claimed that, contrary to popular belief, the vaccines were not originally produced by the pharmaceutical companies. Government documents confirm his claim. “There were 138 companies that were involved in manufacturing and distributing the vaccine. They’re all military contractors. The Pentagon and the National Security Agency ran the entire pandemic response.” He said that “Pfizer and Moderna don’t really own those vaccines. They slap their labels on them, but it was a Pentagon project.”‘Operation Warp Speed’ under former President Trump was an interagency partnership between the Department of Health and Human Services (HHS) and the military Department of Defense (DOD). The DOD wrote: “The Defense Department is working closely with the Federal Emergency Management Agency, the Department of Homeland Security, the Department of Health and Human Services and the State Department to provide support in dealing with the coronavirus pandemic.”

 

 

 

The experimental COVID mRNA vaccine is actually a project of the Pentagon and military, according to Robert F. Kennedy Jr.

Children’s Health Defense founder Robert F. Kennedy Jr. claimed that, contrary to popular belief, the vaccines were not originally produced by the pharmaceutical companies.

“There were 138 companies that were involved in manufacturing and distributing the vaccine. They’re all military contractors. The Pentagon and the National Security Agency ran the entire pandemic response,” Kennedy Jr. said on “The Kim Iversen Show” earlier this month.

Children’s Health Defense founder Robert F. Kennedy Jr. claimed that, contrary to popular belief, the vaccines were not originally produced by the pharmaceutical companies.

“There were 138 companies that were involved in manufacturing and distributing the vaccine. They’re all military contractors. The Pentagon and the National Security Agency ran the entire pandemic response,” Kennedy Jr. said on “The Kim Iversen Show” earlier this month.

“Pfizer and Moderna don’t really own those vaccines. They slap their labels on them, but it was a Pentagon project,” he added.

Government documents confirm Kennedy Jr.’s claim.

From the Congressional Research Service on the vaccine in March 2021:

Operation Warp Speed (OWS) is an interagency partnership between the Department of Health and Human Services (HHS) and the Department of Defense (DOD) that coordinates federal efforts to accelerate the development, acquisition, and distribution of COVID-19 medical countermeasures. Collaborating HHS components include the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA).

Medical device R&D executive Sasha Latypova further explained in a lecture the defense contracts that were used to produce and distribute the COVID-19 mRNA vaccine.

Read full article here…

Link for full interview with Robert Kennedy, Jr:  https://www.bitchute.com/video/j5QVOkjYWCkN/

 


From the Congressional Research Service

Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccination Materials

VIEW FULL PDF HERE with all links: https://crsreports.congress.gov/product/pdf/IN/IN11560

[CONGRESSIONAL RESEARCH SERVICE FULL DOCUMENT also available here: IN11560]

Operation Warp Speed Contracts for
COVID-19 Vaccines and Ancillary
Vaccination Materials
Updated March 1, 2021
Operation Warp Speed (OWS) is an interagency partnership between the Department of Health and
Human Services (HHS) and the Department of Defense (DOD) that coordinates federal efforts to
accelerate the development, acquisition, and distribution of COVID-19 medical countermeasures.
Collaborating HHS components include the Centers for Disease Control and Prevention (CDC), the
National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority
(BARDA). OWS is a Trump Administration initiative, and while the Biden Administration has indicated
that the interagency response to COVID-19 will continue, it plans to restructure and rename the effort.
Although the stated goals of OWS include therapeutics and diagnostics, most of the money awarded to
date has focused on vaccines. This Insight summarizes OWS’s vaccine-related contracts, including those
for ancillary vaccination materials (e.g., needles and vials).
BARDA is currently supporting six vaccine candidates through funding research and development,
funding increases in manufacturing capacity, and/or advance purchase contracts. A vaccine candidate
from Merck/IAVI also received funding support from BARDA, but was discontinued in January 2021
because it failed to demonstrate sufficient efficacy against COVID-19. Table 1 provides BARDA contract
awards and additional information about these candidates.
Vaccine development, like drug development, is generally an expensive process that takes 10 or more
years. To accelerate development, OWS implemented a number of measures, including supporting
increased manufacturing capacity for some of the vaccine candidates while they were still in testing,
rather than waiting until testing was complete to scale up production. This investment is considered “atrisk,” in that the federal government is paying to develop or manufacture vaccine candidates that may not
prove to be safe or effective.
Vaccine candidates that received federal government support for development include Moderna, Janssen
Pharmaceuticals, Sanofi/GSK, and Merck/IAVI (see Table 1), whereas the Pfizer/BioNTech, Janssen, and
Novavax candidates participated in OWS through federal purchase of doses only. Three manufacturers
have received Emergency Use Authorization (EUA) from the Food and Drug Administration for their vaccine candidates: Pfizer/BioNTech, Moderna, and Johnson & Johnson. Because OWS has purchased these vaccines, all doses are federally owned and will be provided at no cost to the American public.

The Government Accountability Office has noted difficulties in assessing supply chain transparency for vaccines and ancillary supplies. Shortages of ancillary supplies in particular have been a concern before and throughout the vaccination campaign.

Although the Biden Administration has announced efforts to increase the production and acquisition of ancillary supplies—including entering into new contracts and invoking the Defense Production Act— monitoring and addressing potential supply issues may still be of interest to Congress. Table 2 provides OWS contract awards for ancillary vaccination supplies.

 

 

Author Information
Simi V. Siddalingaiah
Analyst in Health Economics

Disclaimer

This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan shared staff
to congressional committees and Members of Congress. It operates solely at the behest of and under the direction of Congress. Information in a CRS Report should not be relied upon for purposes other than public understanding of information that has been provided by CRS to Members of Congress in connection with CRS’s institutional role.

CRS Reports, as a work of the United States Government, are not subject to copyright protection in the United
States. Any CRS Report may be reproduced and distributed in its entirety without permission from CRS. However,
as a CRS Report may include copyrighted images or material from a third party, you may need to obtain the
permission of the copyright holder if you wish to copy or otherwise use copyrighted material.